How ESE is Funded

The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2019 financial year.

ESE is funded through a number of industry and non-industry sources;

  • Membership – individual
  • Membership – Corporate – See all our Corporate members
  • Revenue generated by ESE owned journal ‘European Journal of Endocrinology
  • Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education 
  • The list of all industry and non-industry revenue sources in 2019 are listed below: 
  1. Advanced Accelerator Applications
  2. Aegerion Pharmaceuticals
  3. AmCad
  4. Ascendis Pharma
  5. Avanti Polard Lipids
  6. Chiasma
  7. Clinical Endocrinology Trust
  8. Corcept
  9. Eli Lilly
  10. HRA Pharma
  11. Ipsen
  12. ITM (Isotopen Technologies Munchen)
  13. Merck
  14. Novartis
  15. Novo Nordisk
  16. Otsuka
  17. Pfizer
  18. Sandoz/Hexal
  19. Shire/Takeda
  20. Siemens
  21. Strongbridge
  22. Taureon
  23. The Company of Biologists
  24. ThermoFisher
  25. Unipharma
  26. Wisepress
  • Of the revenue into ESE in the 2019 accounts 39.5% was provided by industry
  • The highest contribution from a single company represented 17% of the industry revenue and 6% of ESE revenue overall.